Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in Advanced and Early HR+ Breast Cancer Expert Perspectives on CDK4 and 6 Inhibitors and Other Novel Agents

1.50 hr(s) | CME , MOC , ABIM

Specialty: Breast Cancer

Therapeutic Area(s): Oncology

Release Date: June 17, 2021

Expiration Date: June 17, 2021

Location: Live Webcast

The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs), among many others. Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView Live web broadcast, developed in collaboration with top experts and in partnership with the Tigerlily Foundation, will focus on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs.

Access this activity
Share via
Copy link
Powered by Social Snap